Stock 6826 SHANGHAI HAOHAI BIOLOGICAL TECHNOLOGY CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Shanghai Haohai Biological Technology Co., Ltd.

Equities

6826

CNE100001W69

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:22 2024-04-29 am EDT 		5-day change 1st Jan Change
41.55 HKD +1.47% Intraday chart for Shanghai Haohai Biological Technology Co., Ltd. +11.10% +3.10%
Mar. 11 Shanghai Haohai's 2023 Profit Rises on Higher Revenue; Shares Rise 5% MT
Mar. 08 Shanghai Haohai Biological Technology Co., Ltd. Proposes Final Dividend for the Year Ended December 31, 2023, Payable on July 19, 2024 CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Shanghai Haohai's 2023 Profit Rises on Higher Revenue; Shares Rise 5%
MT
Shanghai Haohai Biological Technology Co., Ltd. Proposes Final Dividend for the Year Ended December 31, 2023, Payable on July 19, 2024
CI
Shanghai Haohai Biological Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Shanghai Haohai Biological Forecasts Up to 138% Boost in 2023 Profit
MT
Shanghai Haohai Biological Technology Co., Ltd. Provides Preliminary Unaudited Consolidated Group Earnings Guidance for the Year Ended 31 December 2023
CI
Tranche Update on Shanghai Haohai Biological Technology Co., Ltd.'s Equity Buyback Plan announced on September 27, 2023.
CI
Haohai Biological Technology's Q3 Profit Rises 34%; Hong Kong Shares Jump 5%
MT
Shanghai Haohai Biological Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Tranche Update on Shanghai Haohai Biological Technology Co., Ltd.'s Equity Buyback Plan announced on September 27, 2023.
CI
Shanghai Haohai Biological Technology Co., Ltd. commences an Equity Buyback Plan for 1,538,461 shares, representing 0.9% for CNY 200 million, under the auhtorization approved on September 15, 2023.
CI
Shanghai Haohai Biological Technology to See Rise in January-September Profit
MT
Shanghai Haohai Biological Technology Co., Ltd. Provides Unaudited Consolidated Financial Guidance for the Nine Months Ended 30 September 2023
CI
Shanghai Haohai Biological Technology's Profit Surges 188.9% in H1; Shares Up 3%
MT
Shanghai Haohai Biological Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Shanghai Haohai Biological Technology Co., Ltd. authorizes a Buyback Plan.
CI
Shanghai Haohai Biological to Buy Remaining Stake in Medical Aesthetics, Cosmetology Business
MT
Shanghai Haohai Biological Technology Co., Ltd. entered into the equity transfer agreement to acquire 36.3636% stake in OHMK Medical Technology Co., Ltd. from Tianjin Huacan Enterprise Management Consulting Partnership, Shanghai Ermei Enterprise Management Consulting Partnership, Yuan Yibing, Lian Songyong and Chen Guangfei for approximately CNY 150 million.
CI
Shanghai Haohai Biological Technology’s H1 Profit to See Up to 210% Boost
MT
Shanghai Haohai Biological Technology Co., Ltd. Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2023
CI
Shanghai Haohai Biological Technology Co., Ltd. Approves Final Dividend for the Year Ended 31 December 2022, Payable on August 11, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 6826 Stock
  4. News Shanghai Haohai Biological Technology Co., Ltd.
  5. Highlights